Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in JapanArticle Published on 2022-11-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval 95%CI adjusted odds ratio age analyzed anti-spike antibody Antibody Response BNT162b2 BNT162b2 mRNA booster vaccination Booster vaccine Cohort Coverage COVID-19 decrease dose Effectiveness eight Factor group groups HCW HCWs Health care worker healthcare worker Increased infection control interquartile range introduced IQR Japan median mRNA vaccine multivariate logistic regression no significant difference not significant positive risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections subject university vaccination Vaccine waning immunity [DOI] 10.1016/j.jiac.2022.07.010 PMC 바로가기
Targeting SARS-CoV-2 papain-like protease in the postvaccine eraArticle Published on 2022-11-012022-11-15 Journal: Trends in pharmacological sciences [Category] SARS, 치료제, [키워드] approval artificial intelligence Compound computer-aided drug design COVID-19 Critical direct-acting antiviral drug drugs expected global healthcare Host innate immune response methodology Papain-like protease PLPro Rapid responses SARS-CoV-2 SARS-CoV-2 protein Small molecules small molecules. targeting therapeutic target Vaccine viral replication waning immunity while [DOI] 10.1016/j.tips.2022.08.008 PMC 바로가기
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI appear applied approach Blood booster booster vaccination Booster vaccine Cellulose country COVID COVID-19 pandemic decrease evaluate evaluated heterogeneity immune response Immunity immunological protection increase in indicated individual individual level induce median MONITOR NAb Neutralization antibody Neutralizing Neutralizing antibodies neutralizing antibody omicron Omicron variant pandemic POC point of care point-of-care point-of-care test population level predominant Protective Rapid regimen reported responses against SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants shown stick switching vaccination variant variants of concern variants of SARS-CoV-2 virus neutralization test VoC VOCs waning immunity wild-type [DOI] 10.1128/spectrum.02257-22 PMC 바로가기
Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseasesArticle Published on 2022-10-132022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-SARS-CoV-2 anti-spike-IgG antibody Antibody Response baseline benefit blood sample BNT162b2 Cohort combination therapy COVID-19 COVID-19 vaccination COVID-19 vaccine disease Effect elderly patients eligible examined highest humoral immunogenicity identifying immunomodulatory Immunosuppression increased risk Inflammatory medication monotherapy mRNA mRNA vaccine mRNA-1273 Odds ratio outcomes Patient patients provided recruited reduced response rheumatic disease SARS-CoV-2 SARS-COV-2 infection significantly lower spike IgG Support tested the disease the vaccine Treatment Type vaccination vaccine dose waning immunity [DOI] 10.3389/fimmu.2022.1016927 PMC 바로가기
Susceptibility to Resurgent COVID-19 Outbreaks Following Vaccine Rollouts: A Modeling StudyArticle Published on 2022-10-122022-11-16 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, [키워드] affecting Asymptomatic Characteristics compartmental model conditions contagious country Coverage COVID-19 COVID-19 vaccine COVID-19 vaccines Effect Effectiveness Endemic Epidemics epidemiological expand explain Health help Immunity include initial key factor modeling parameter populations reported resurgent epidemics SARS-CoV-2 SARS-CoV-2 variants Spread susceptibility the disease the SARS-CoV-2 virus the vaccine vaccination vaccination coverage waning immunity [DOI] 10.3390/v14102237 PMC 바로가기
A bivalent SARS-CoV-2 monoclonal antibody combination does not affect the immunogenicity of a vector-based COVID-19 vaccine in macaquesArticle Published on 2022-10-052022-11-15 Journal: Science Translational Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Adenovirus Administered administration Affect approach cellular immunity coronavirus coronavirus disease COVID-19 COVID-19 vaccine cynomolgus macaques evaluate Human humoral mAb mAbs macaque monoclonal antibody monoclonal antibody combination not affect offer required SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant spike glycoprotein the vaccine Treatment vaccinated individuals vaccination rates Vaccine viral vector-based waning immunity [DOI] 10.1126/scitranslmed.abo6160 PMC 바로가기
A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?Article Published on 2022-09-162022-11-15 Journal: Medicine [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome Adequate administration benefit booster booster dose booster vaccinations Breakthrough infection conducted coronavirus coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine debates demonstrated dose Effect ENhance Evidence General population healthcare Immunity Immunocompromised patient individuals information Initially lack maintain neutralizing antibody pandemic raised reported required Safe second dose the vaccine trajectory vaccination Vaccine Vaccine-induced immunity variants Viral variants waning immunity [DOI] 10.1097/MD.0000000000030609 PMC 바로가기
Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional surveyArticle Published on 2022-09-142022-11-16 Journal: BMC Public Health [Category] SARS, 변종, [키워드] Analysis Annual benefit booster dose chronic conducted COVID-19 COVID-19 disease COVID-19 vaccine cross-sectional cross-sectional survey determine dose doses Effectiveness facilitate Factor Factors Government higher education higher odd identify identity immunization increasing age Infection influences on Influenza influenza vaccine Intention multinomial logistic regression National new SARS-CoV-2 Offering Pharmacy populations preference primary dose receive recommendation refusal reported required seasonal Sociodemographic targeted intervention third dose transition vaccination Vaccine vaccine dose variants waning immunity were used widespread [DOI] 10.1186/s12889-022-14025-8 PMC 바로가기
A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospectsArticle Published on 2022-09-132022-11-16 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] Administered Adults age antigenic approved booster children clinical development comparable country CoV COVID-19 pandemic COVID-19 severity disease Effectiveness Efficacy Emergency use Emergency use authorization generate geometric mean titer group Healthcare system Heterologous heterologous prime and boost vaccines heterologous prime-boost immune response inactivated Inactivated vaccine inactivated virus adjuvanted vaccine increase in India induce Like memory B morbidity Mortality neutralization neutralization titer original antigenic sin over pandemic pediatric phase Population prime and boost reactogenicity reduce reduction in robust safety profile SARS – CoV – 2 SARS-CoV-2 variant seroconversion rate symptomatic COVID-19 disease synergy T-cell responses TLR7/8 vaccinated individuals vaccination Vaccine vaccine challenges Vaccine development vaccine dose Vaccines variants of concern variants of concern (VOCs) virus VOCs waning immunity [DOI] 10.3389/fimmu.2022.940715 PMC 바로가기
Surface Inactivation of Highly Mutated SARS-CoV-2 Variants of Concern: Alpha, Delta, and OmicronArticle Published on 2022-09-122022-11-16 Journal: Biomacromolecules [Category] SARS, 변종, [키워드] adaptive Alpha Antiviral Complete Degradation Delta dominant effective Evolution Face mask glycosylated inactivation independent induce Infection ingestion Mask mice mutations non-toxic omicron Omicron variant pandemic physical barrier Polymer reduction SARS-CoV-2 SARS-CoV-2 transmission Spike protein Spread surface Transmission Vaccine variant variants variants of concern viral genome viral membrane virion virulence virus VoC VOCs waning immunity [DOI] 10.1021/acs.biomac.2c00801 PMC 바로가기